Covered recipient · General Payments record
JIN XU
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2023
$8,524.85
- Reported across 571 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $672.35 | 41 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $196.00 | 14 |
| Lilly USA, LLC | $138.72 | 8 |
| Novo Nordisk AS | $104.41 | 5 |
| Acerta Pharma LLC | $85.64 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $46.87 | 3 |
| PFIZER INC. | $45.90 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $39.60 | 2 |
| Amarin Pharma Inc. | $15.21 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (41)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.